UNSPSC 51332830: Thioridazine

This classification denotes an antipsychotic agent with the molecular formula C21H26N2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N3D6TG58NI, chemically known as 10h-phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylthio)- but generally known as thioridazine, which bears US NIH Compound Identifier 5452. European Medicines Agency schedules Thioridazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10984MIG.

UNSPSC 51332830 Thioridazine is a Commodity code that nominally covers a specific antipsychotic medication, but recent state and local procurement activity under this code shows little direct solicitation for thioridazine itself. Instead, the code appears in broader pharmaceutical and health-supply procurement contexts where state and local agencies are acquiring multiple drug products, OTC items, and medical supplies through competitive bidding and cooperative purchasing frameworks. State and local issuing bodies under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that serve participating state and local government facilities. The scope of work encompasses supply agreements for generic pharmaceuticals, OTC products, naloxone, and drug deactivation systems, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) adherence, insurance coverage requirements, and electronic submission protocols through state procurement portals or eProcurement systems.

Recent activity is concentrated in Florida and Minnesota, with multistate coordination through cooperative purchasing vehicles. Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, a two-year term with one-year renewal option, and a July 26, 2023, response deadline. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) posted January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026, evaluation weighted 75 percent on price competitiveness, and contract awards effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription programs as exploratory market intelligence ahead of formal procurement strategy.